AnaptysBio’s (ANAB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of AnaptysBio (NASDAQ:ANAB) in a report issued on Monday,Benzinga reports. The brokerage currently has a $95.00 price target on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on ANAB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th. UBS Group boosted their price target on AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Barclays upped their price objective on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, Piper Sandler decreased their target price on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $80.00.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $58.00 on Monday. The company’s 50 day simple moving average is $58.58 and its 200 day simple moving average is $59.02. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -53.70 and a beta of 0.72. AnaptysBio has a 1 year low of $11.40 and a 1 year high of $72.36.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Persistent Asset Partners Ltd bought a new position in AnaptysBio in the second quarter valued at about $39,000. Smartleaf Asset Management LLC grew its holdings in shares of AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. increased its stake in shares of AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.